Parma, Italy-based Chiesi Farmaceutici S.p.A. announced its acquisition of Amryt Pharma PLC (NASDAQ: AMYT) for $1.25 billion.
Centerview Partners LLC served as exclusive financial advisor and Dechert LLP was the legal advisor to Chiesi. Moelis & Company LLC served as exclusive financial advisor and Cooley LLP and Gibson Dunn & Crutcher LLP were the legal advisors to Amryt.
Amryt Pharma is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. It was founded in 2015 and is based in Dublin, Ireland. In 2022, the company reported revenue of $220 million.
Chiesi Farmaceutici S.p.A. is a research-focused international company developing added-value, innovative pharmaceutical solutions. In 2021, the company reported turnover of $2.63 billion (€2.42 billion).
Chiesi will purchase all outstanding shares of Amryt for a purchase price per American Depositary Share of Amryt, which each represent 5 Amryt ordinary shares, of $14.50 (or $2.90 per ordinary share) in cash, plus contingent value rights of up to $2.50 per ADS payable if certain milestones related to Amryt’s product Filsuvez are achieved.
According to data captured in the LevinPro HC database, this acquisition represents the third Pharmaceuticals transaction of 2023. In 2022, there were 96 Pharmaceutical transactions.
